Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison

por Home, Philip D., Mehta, Roopa, Hafidh, Khadija A. S., Gurova, Olesya Y., Alvarez, Agustina, Serafini, Paul, Pourrahmat, Mir‐Masoud
Publicado 2021

Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix tria...

por McCrimmon, Rory J., Home, Philip, Cheng, Alice, Giorgino, Francesco, Fonseca, Vivian, Souhami, Elisabeth, Alvarez, Agustina, Picard, Pascaline, Rosenstock, Julio
Publicado 2022

Improved patient‐reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial

por Polonsky, William H., Giorgino, Francesco, Rosenstock, Julio, Whitmire, Katherine, Lew, Elisheva, Coudert, Mathieu, Alvarez, Agustina, Nicholls, Charlie, McCrimmon, Rory J.
Publicado 2022

Advancing Therapy in Suboptimally Controlled Basal Insulin–Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Tri...

por Rosenstock, Julio, Emral, Rifat, Sauque-Reyna, Leobardo, Mohan, Viswanathan, Trescolí, Carlos, Al Sifri, Saud, Lalic, Nebojsa, Alvarez, Agustina, Picard, Pascaline, Bonnemaire, Mireille, Demil, Nacima, McCrimmon, Rory J.
Publicado 2021